Results 161 to 170 of about 22,968 (195)

Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review. [PDF]

Cancer Rep (Hoboken)
Fu PA, Hsu YC, Hsu HP, Lin TC, Chung WP.
europepmc   +1 more source

Extracellular matrix-derived mechanical force induces CDK4/6 inhibitor resistance by inhibiting NEK10 dependent cell cycle regulation in breast cancer. [PDF]

Int J Surg
Li C, Wang J, Jin Y, Huang Y, Hong R, Chen D, Lin S, Chen L, Wu H, Du T, Xu B, Wang W, Wang S.   +12 more
europepmc   +1 more source

CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. [PDF]

Discov Oncol
Sun Y, Zhao Y, Yu X, Qi Y, Dai X.
europepmc   +1 more source

Matricellular protein SMOC2 safeguards tubular integrity in acute kidney injury via integrin β3-dependent inhibition of CCND1-CDK4/6 axis. [PDF]

Mol Biomed
Gao P, Cenatus S, Zhang D, Chu S, Henley N, Pichette V, Barrera-Chimal J, Gerarduzzi C.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Palbociclib

Reactions Weekly, 2021
  +11 more sources

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer [PDF]

New England Journal of Medicine, 2015
Massimo Cristofanilli
exaly   +5 more sources

Palbociclib

pharma-kritik, 2017
Mit Palbociclib können Patientinnen mit einem fortgeschrittenen Mammakarzinom, das bestimmte Eigenschaften aufweist, behandelt werden. In Kombination mit Fulvestrant oder Letrozol kann damit das «progressionsfreie Überleben» signifikant verlängert werden. Ob die Behandelten gesamthaft länger überleben, ist bisher nicht gesichert.    
  +4 more sources